HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djac227
Abstract: In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown.… read more here.
Keywords: her2dx; erbb2 mrna; advanced her2; breast cancer ... See more keywords